WeVote
Log In

Bill

Bill

SB 152

AN ACT ADOPTING THE HUMAN CELL PRODUCT LABELING ACT.

2025 Regular Session Introduced by Rob Sampson

Connecticut bill requiring labeling disclosure of human cell-derived materials in commercial products to increase consumer transparency about cellular content.

REF. TO JOINT COMM. ON General Law
#disclosure #labeling #products #stemcellresearch
0
WeVote Research Nonpartisan
Bill Summary · SB 152

Legislative bill overview

SB 152 would establish labeling requirements for products containing human cells or human cell-derived materials sold in Connecticut. The bill creates standards for disclosure and transparency regarding the source, type, and processing of human cellular materials used in commercial products, potentially affecting cosmetics, pharmaceuticals, supplements, and medical devices.

Why is this important

As biotechnology and cellular engineering advance, products increasingly contain human-derived materials—from lab-grown skin cells in cosmetics to processed placental compounds in supplements. Clear labeling requirements help consumers make informed choices and understand what they're purchasing, while also establishing consistent state standards that manufacturers must follow.

Potential points of contention

  • Industry compliance costs: Manufacturers may argue that new labeling requirements impose significant testing, reformulation, and administrative expenses, particularly for small companies
  • Scope ambiguity: Disagreement over which products fall under "human cell products" (does this include trace elements, derivatives, or only direct cellular material?) could create legal uncertainty
  • Interstate commerce concerns: Connecticut-only labeling standards might conflict with federal FDA regulations or create barriers for national product distribution, prompting constitutional commerce clause challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.